Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB248 + Tarlatamab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB248 | AB-248|AB 248 | AB248 is a fusion protein comprised of an anti-CD8 antibody fused to an IL-2 mutein, which preferentially targets CD8+ T-lymphocytes, potentially resulting in increased antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 3518). | ||
| Tarlatamab | Imdelltra | AMG 757|AMG757|AMG-757|tarlatamab-dlle | CD3 Antibody 119 DLL3 Antibody 10 | Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07037758 | Phase I | AB248 + Tarlatamab | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) (DeLLphi-311) | Recruiting | USA | TUR | 0 |